IP Library Granted Patent US 11,987,792
Granted Patent B2
US 11,987,792 · App. 17/268,206 · Granted May 21, 2024

Compositions and methods for inhibiting expression of the LECT2 gene

Inventors: Gregory Hinkle (Plymouth, MA); Huilei Xu (Cambridge, MA)
Assignee: ALNYLAM PHARMACEUTICALS, INC.
C12N15/113A61K9/0019A61K9/08A61K9/5123A61K47/02C12N2310/14C12N2310/321C12N2310/322C12N2310/351C12N2310/3515C12N2320/32C12N2320/35
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,987,792
App. No.
17/268,206
Granted
May 21, 2024
Kind
B2
Abstract

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the LECT2 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of LECT2.

Claims (22)

1. A double-stranded ribonucleic acid (dsRNA) for inhibiting expression of LECT2, wherein said dsRNA comprises a sense strand and an antisense strand, the antisense strand comprising a region of complementarity to a LECT2 RNA transcript, wherein the antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the antisense sequence and all the modifications of SEQ ID NO: 93 or 290 and the sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the sense sequence and all the modifications of SEQ ID NO: 92 or 289.

2. The dsRNA of claim 1 , wherein the dsRNA comprises a duplex region that is 15-30 nucleotide pairs in length.

3. The dsRNA of claim 1 , wherein the region of complementarity is at least 17 nucleotides in length.

4. The dsRNA of claim 1 , wherein at least one strand comprises a 3′ overhang of at least 1 nucleotide.

5. The dsRNA of claim 1 , wherein the dsRNA comprises a duplex region that is 17-23 nucleotide pairs in length.

6. The dsRNA of claim 1 , wherein the dsRNA comprises a duplex region that is 19-21 nucleotide pairs in length.

7. The dsRNA of claim 1 , wherein the dsRNA comprises a duplex region that is 21-23 nucleotide pairs in length.

8. The dsRNA of claim 1 , wherein at least one strand comprises a 3′ overhang of at least 2 nucleotides.

9. The dsRNA of claim 1 , wherein the region of complementarity is 19 nucleotides in length.

10. The dsRNA of claim 1 , wherein the region of complementarity is between 19 and 21 nucleotides in length.

11. The dsRNA of claim 1 , wherein

(a) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 92 and the antisense strand comprises the sequence and all the modification of SEQ ID NO: 93; or

(b) the sense strand comprises the sequence and all the modifications of SEQ ID NO: 289 and the antisense strand comprises the sequence and all the modification of SEQ ID NO: 290.

12. The dsRNA of claim 1 , wherein the sense strand is conjugated to at least one ligand.

13. The dsRNA of claim 12 , wherein the ligand is a GalNAc ligand.

14. The dsRNA of claim 12 , wherein the ligand is

15. The dsRNA of claim 12 , wherein the ligand is attached via a linker.

16. The dsRNA of claim 15 , wherein the ligand and linker are as shown in Formula XXIV:

17. A pharmaceutical composition for inhibiting expression of a LECT2 gene, the composition comprising the dsRNA of claim 1 .

18. An isolated cell containing the dsRNA of claim 1 .

19. A vector encoding at least one strand of the dsRNA of claim 1 .

20. An isolated cell comprising the vector of claim 19 .

Assignments (1)
SECURITY INTEREST Recorded Oct 1, 2025
From: ALNYLAM PHARMACEUTICALS, INC.; SIRNA THERAPEUTICS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 072996/0337 →
Continuity (2)
Provisional Application 62764909 · Aug 16, 2018
Related Publication 20210348162A1 · Nov 11, 2021